493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797629650307907584 |
|---|---|
| author | Vanessa Gauttier Marion Drouin Caroline Mary Géraldine Teppaz Ariane Desselle Virginie Thépénier Emmanuelle Wilhelm Elise Chiffoleau Nicolas Poirier Isabelle Girault Cecile Batty Marine Malloci Julien Taurelle Irène Baccelli Stéphanie Neyton Mylène Deramé Kevin Biteau Marion Colonello |
| author_facet | Vanessa Gauttier Marion Drouin Caroline Mary Géraldine Teppaz Ariane Desselle Virginie Thépénier Emmanuelle Wilhelm Elise Chiffoleau Nicolas Poirier Isabelle Girault Cecile Batty Marine Malloci Julien Taurelle Irène Baccelli Stéphanie Neyton Mylène Deramé Kevin Biteau Marion Colonello |
| author_sort | Vanessa Gauttier |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:56:08Z |
| format | Article |
| id | doaj.art-45af6b22c7b64833b57d18e90b652885 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:56:08Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-45af6b22c7b64833b57d18e90b6528852023-11-13T06:55:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0493493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical modelsVanessa Gauttier0Marion Drouin1Caroline Mary2Géraldine Teppaz3Ariane Desselle4Virginie Thépénier5Emmanuelle Wilhelm6Elise Chiffoleau7Nicolas Poirier8Isabelle Girault9Cecile Batty10Marine Malloci11Julien Taurelle12Irène Baccelli13Stéphanie Neyton14Mylène Deramé15Kevin Biteau16Marion Colonello17OSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, FranceOSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France2CRTI – UMR1064, Nantes, France1OSE Immunotherapeutics, Nantes, FranceOSE Immunotherapeutics, Nantes, Loire-Atlantique, FranceOSE Immunotherapeutics, Nantes, Loire-Atlantique, FranceOSE Immunotherapeutics, Nantes, Loire-Atlantique, FranceOSE Immunotherapeutics, Nantes, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France1OSE Immunotherapeutics, Nantes, Loire-Atlantique, France |
| spellingShingle | Vanessa Gauttier Marion Drouin Caroline Mary Géraldine Teppaz Ariane Desselle Virginie Thépénier Emmanuelle Wilhelm Elise Chiffoleau Nicolas Poirier Isabelle Girault Cecile Batty Marine Malloci Julien Taurelle Irène Baccelli Stéphanie Neyton Mylène Deramé Kevin Biteau Marion Colonello 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models Journal for ImmunoTherapy of Cancer |
| title | 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models |
| title_full | 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models |
| title_fullStr | 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models |
| title_full_unstemmed | 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models |
| title_short | 493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models |
| title_sort | 493 identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint clec 1 and their associated anti tumoral in vivo efficacies in humanized preclinical models |
| work_keys_str_mv | AT vanessagauttier 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT mariondrouin 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT carolinemary 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT geraldineteppaz 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT arianedesselle 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT virginiethepenier 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT emmanuellewilhelm 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT elisechiffoleau 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT nicolaspoirier 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT isabellegirault 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT cecilebatty 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT marinemalloci 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT julientaurelle 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT irenebaccelli 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT stephanieneyton 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT mylenederame 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT kevinbiteau 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels AT marioncolonello 493identificationofdifferentclassesofantagonistmonoclonalantibodiestargetingthemyeloidcheckpointclec1andtheirassociatedantitumoralinvivoefficaciesinhumanizedpreclinicalmodels |